Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_4
1
14%
Ph early_phase_1
1
14%
Ph phase_2
2
29%
Ph phase_1
3
43%

Phase Distribution

4

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (14.3%)
Phase 13 (42.9%)
Phase 22 (28.6%)
Phase 41 (14.3%)

Trials by Status

completed571%
terminated229%

Recent Activity

0 active trials
Showing 5 of 7
completedearly_phase_1

Washington University WU 409: Immune Responses to Rabies Vaccine.

NCT07399951
terminatedphase_1

A Study of RBI-4000 in Healthy Participants

NCT06048770
completedphase_1

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

NCT04062669
terminatedphase_4

Antibody Production in Immune Disorders

NCT00023504
completedphase_2

Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine

NCT00223990
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07399951Early Phase 1

Washington University WU 409: Immune Responses to Rabies Vaccine.

Completed
NCT06048770Phase 1

A Study of RBI-4000 in Healthy Participants

Terminated
NCT04062669Phase 1

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

Completed
NCT00023504Phase 4

Antibody Production in Immune Disorders

Terminated
NCT00223990Phase 2

Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine

Completed
NCT03264157Phase 2

Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects

Completed
NCT02956746Phase 1

A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7